Skip to content
Research Article Open access CC BY 4.0

The Potential Use of Blood, Cerebrospinal Fluid, Saliva and Urine as Biological Samples for the Diagnosis of Alzheimer’s Disease

Adnan Awn Algarni, Abdulhadi I. Bima, Ayman Z. Elsamanoudy

International Journal of Biochemistry Research & Review · pp. 26–41 · Published 3 Aug 2020

10.9734/ijbcrr/2020/v29i830210

Abstract

Background and Aim: Alzheimer’s disease (AD) is the most common cause of dementia. 80% of all dementia is due to AD. Diagnosis of AD is a difficult task, as the accurate diagnosis requires post-mortem examination of brain autopsy samples. Diagnosis of AD in living individuals can be aided by the establishment of the clinical criteria, positron emission tomography (PET) examination, and biomarkers. The study of biomarkers for diagnosis of AD could help clinicians to evaluate individuals at risk, and confirm the occurrence as well as the progression of AD in a non-invasive manner. High sensitivity and high specificity of the used markers are mandatory criteria for these biomarkers to trusted for AD diagnosis and prognosis. So, this review article aims to focus on the potential use of body fluids as a source of the biomarkers that are used for investigating patients with AD. Methodology: In the current study, we reviewed scientific articles that discuss AD pathogenesis and diagnosis of Google Scholar database, Pubmed, Pubmed Central, Cochrane Database of Systematic Reviews (CDSR), MEDLINE, and MedlinePlus with no time limitation. Moreover, we discussed the use of recently discovered biomarkers that are detected in blood, CSF, saliva, and urine. Conclusion: In the current review, it could be concluded that in addition to the blood and cerebrospinal fluid as common biological samples for the diagnosis of AD, saliva and urine are useful potential biological samples. Moreover, both are noninvasive samples that give them priority to be used.

Alzheimer’s disease biomarkers biological samples blood CSF saliva urine

References (32)

  1. 1 The neuropathological diagnosis of Alzheimer’s disease [DOI]
  2. 2 Variant of TREM2 Associated with the Risk of Alzheimer's Disease [DOI]
  3. 3 Biomarker Modeling of Alzheimer’s Disease [DOI]
  4. 4 Brain-Gut-Microbiota Axis in Alzheimer’s Disease [DOI]
  5. 5 Alzheimer’s disease prevention: from risk factors to early intervention [DOI]
  6. 6 TDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia [DOI]
  7. 7 CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease [DOI]
  8. 8 Application of Metabolomics in Alzheimer’s Disease [DOI]
  9. 9 Biomarkers of Alzheimer disease in plasma [DOI]
  10. 10 Epidemiological and Economic Burden of Alzheimer's Disease: A Systematic Literature Review of Data across Europe and the United States of America [DOI]
  11. 11 Homocysteine and Neurologic Disease [DOI]
  12. 12 Candidate Blood Proteome Markers of Alzheimer's Disease Onset and Progression: A Systematic Review and Replication Study [DOI]
  13. 13 Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study [DOI]
  14. 14 Review: Tau in biofluids – relation to pathology, imaging and clinical features [DOI]
  15. 15 Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort [DOI]
  16. 16 Diagnostic Biomarkers of Alzheimer’s Disease as Identified in Saliva using 1 H NMR-Based Metabolomics [DOI]
  17. 17 Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic [DOI]
  18. 18 Lipidomics by ultrahigh performance liquid chromatography-high resolution mass spectrometry and its application to complex biological samples [DOI]
  19. 19 The Cerebrospinal Fluid Aβ 1–42 /Aβ 1–40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer’s Disease in a Clinical Setting [DOI]
  20. 20 Metabolomics Analyses of Saliva Detect Novel Biomarkers of Alzheimer’s Disease [DOI]
  21. 21 Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves micro RNA ‐195 down‐regulation [DOI]
  22. 22 Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies [DOI]
  23. 23 Reduction of SorLA/LR11, a Sorting Protein Limiting β-Amyloid Production, in Alzheimer Disease Cerebrospinal Fluid [DOI]
  24. 24 Plasminogen activator activity is inhibited while neuroserpin is up‐regulated in the Alzheimer disease brain [DOI]
  25. 25 Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer’s Disease [DOI]
  26. 26 New Criteria for Alzheimer Disease and Mild Cognitive Impairment [DOI]
  27. 27 The level of Alzheimer-associated neuronal thread protein in urine may be an important biomarker of mild cognitive impairment [DOI]
  28. 28 CSF Amyloid-β Peptides in Neuropathologically Diagnosed Dementia with Lewy Bodies and Alzheimer's Disease [DOI]
  29. 29 Treatment of Sleep Disturbance May Reduce the Risk of Future Probable Alzheimer’s Disease [DOI]
  30. 30 Lipoprotein(a) and Cognitive Performances in an Elderly White Population [DOI]
  31. 31 RIPK1 promotes inflammation and β-amyloid accumulation in Alzheimer’s disease [DOI]
  32. 32 Proteolytic Degradation of Amyloid -Protein [DOI]

Cited by 2

The impact of biomarkers on the pre-diagnosis and treatment of Alzheimer’s disease: A comprehensive review

A. Mittal, Preeti Bhadana, Arpana Pathak · Next Nanotechnology · 2026

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

2

Page views

0

PDF downloads

0

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.